Azenta Inc (AZTA)

Shares of Azenta (AZTA) fell nearly 12% after the company announced the resignation of its President, CEO, and director, John Marotta, who will be replaced by board member Martin Madaus. Despite the company reaffirming its revenue guidance, investors showed concern over the unexpected leadership change and the associated costs, especially since the fiscal 2026 guidance trails management's long-term growth model.

John P. Marotta has resigned as President and CEO of Azenta, Inc. (NASDAQ:AZTA) effective August 22, 2026. The Board of Directors has appointed Dr. Martin D. Madaus as Interim President and CEO. Dr. Madaus, a current Board member, will also assume principal executive officer duties for SEC filings, and his compensation for this interim role is currently under review.

Azenta Inc. has appointed Dr. Martin Madaus as interim President and CEO following the resignation of John Marotta, while reaffirming its Q4 fiscal 2026 revenue guidance. Madaus, a board member with extensive industry experience, will lead the company through this transition, focusing on profitability improvement and capital allocation. The company also clarified that adjusted EBITDA would be affected by a one-time $3 million consulting expense but otherwise reiterated its financial outlook.

This article provides a list of ETFs that hold stocks of Azenta, Inc., sorted by market value. It details various ETFs, including their market value, weight of Azenta, Inc. stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information aims to help investors identify funds that offer diversified exposure to Azenta, Inc. with potentially lower risk.

Azenta (AZTA) recently reported a return to profitability in Q3 2026, with net income of US$2.46 million and revenue of US$161.18 million, alongside a US$50 million share repurchase. The company also raised its full-year revenue guidance to US$613-US$618 million, signaling increased confidence in its operations. While these developments support the bull case for Azenta's long-term profitability in sample management and multiomics, the article cautions that ongoing pressures in certain services and elevated R&D spending could still impact margins and free cash flow.